Get the Stockscreener App
1,014.49
1.85%
-19.07
After Hours:
1011.40
-3.09
-0.30%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,014.49, with a volume of 3.85M.
It is down -1.85% in the last 24 hours and up +11.87% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,033.56
Open:
$1032.625
24h Volume:
3.85M
Relative Volume:
1.03
Market Cap:
$907.99B
Revenue:
$59.42B
Net Income/Loss:
$18.41B
P/E Ratio:
50.17
EPS:
20.2197
Net Cash Flow:
$6.44B
1W Performance:
-8.14%
1M Performance:
+11.87%
6M Performance:
+32.47%
1Y Performance:
+22.25%
1-Day Range:
$1,007.18
$1,032.62
1-Week Range:
$1,007.18
$1,099.05
52-Week Range:
$623.78
$1,111.99
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,014.49 | 925.06B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
202.48 | 494.70B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
228.71 | 406.92B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
132.43 | 256.58B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
100.89 | 253.84B | 63.90B | 19.05B | 13.05B | 7.5596 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
TheWrap, Eli Lilly and Company Toast Dr. Stacy L. Smith With VIP Beverly Hills Dinner | Photos - TheWrap
IU, Eli Lilly ink partnership for clinical trials - WFYI
Lilly and IU announce $40M partnership to expand clinical trial access - Indianapolis Recorder
Eli Lilly and Company (LLY): A bull case theory - MSN
Eli Lilly and Company (LLY): A Bull Case Theory - Finviz
A deal with Donald Trump is boosting this pharma giant - Investors' Chronicle
Eli Lilly (LLY): BMO Capital Raises Price Target, Maintains Rati - GuruFocus
Behind the Scenes of Eli Lilly's Latest Options Trends - Benzinga
Eli Lilly stock price target raised to $1,200 by BMO on obesity drug outlook - Investing.com Canada
Eli Lilly $1 trln value is bet on Coke-like future - Breakingviews
BMO Capital Adjusts PT on Eli Lilly and Company to $1,200 From $1,100, Maintains Outperform Rating - marketscreener.com
FDA approves Eli Lilly’s Jaypirca in relapsed or refractory CLL/SLL - Pharmaceutical Business review -
Eli Lilly, IU agree to $40 million agreement to expand clinical trials - IndyStar
Eli Lilly And Indiana University Sign $40 Mln Agreement To Expand Clinical Trials In Indiana - Nasdaq
Lilly, Indiana University launch new partnership - WTHR
Eli Lilly, Indiana University launch new partnership - wthr.com
Eli Lilly’s Jaypirca Granted Traditional FDA Approval In Treating Certain Cancers - Stocktwits
Lilly Announces Changing The Thread Collection Campaign - InkFreeNews.com
Tag Archives: Changing the Thread Collection - InkFreeNews.com
Lilly and IU partner to enhance clinical trials and treatments for Hoosiers - WISH-TV
Lilly, IU Boost Hoosier Access to Trials, Treatments - Mirage News
Lilly and IU to expand access to clinical trials and latest innovative treatments for Hoosiers - News at IU
Lilly, IU sign clinical trial, research agreement worth up to $40M - Inside INdiana Business
Eli Lilly and Company (LLY) Stock: Gains Expanded FDA Approval for Jaypirca - CoinCentral
1 reason to buy Eli Lilly hand over fist before the new year - MSN
Eli Lilly (LLY) Gains FDA Approval for Expanded Use of Jaypirca - GuruFocus
As Eli Lilly Cuts Zepbound Prices, Should You Buy, Sell, or Hold LLY Stock? - Barchart.com
Morgan Stanley Bullish on Eli Lilly and Company (LLY) - MSN
Eli Lilly announces FDA approval of expanded indication for Jaypirca - TipRanks
Lilly’s Jaypirca receives FDA approval for expanded CLL/SLL use By Investing.com - Investing.com Australia
Eli Lilly (LLY) Secures FDA Approval for Pirtobrutinib in Leukem - GuruFocus
1 Reason to Buy Eli Lilly Hand Over Fist Before the New Year - The Motley Fool
U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor - Eli Lilly and Company
High Margins, 3.5% Discount: Buy Eli Lilly Stock Now - Trefis
Insulin Analog Market Forecasting USD 25.29 Billion Valuation by 2034 - GlobeNewswire Inc.
Eli Lilly Stock Now 3.5% Cheaper, Time To Buy - Trefis
Inside Eli Lilly’s Alzheimer’s campaign blitz during holiday season - PRWeek
Can LLY Strengthen Its Lead as GLP-1 Price Cuts Reshape the Market? - TradingView
Eli Lilly (LLY) Pauses UK Investments Amidst Awaited Drug Approval Changes - GuruFocus
Eli Lilly to delay resuming U.K. investments, FT reports - TipRanks
Eli Lilly not yet ready to unfreeze UK investments, says pharma bossFT - MarketScreener
Lilly builds on BTK inhibitor Jaypirca's 'unique potential impact' with label expansion into earlier lymphoma treatment - Fierce Pharma
Investors have sky-high expectations for Eli Lilly - medwatch.com
Eli Lilly stock price target raised to $1,163 by Guggenheim on GLP-1 growth - Investing.com
Guggenheim Adjusts Price Target on Eli Lilly and Company to $1,163 From $1,036, Maintains Buy Rating - marketscreener.com
Bernstein Reaffirms Price Target on Eli Lilly (LLY) After Breakthrough Gains - MSN
Eli Lilly lowers Zepbound costs amid rising calls for affordability - TechTarget
LLY Lowers Prices of Zepbound Vials for Cash Buyers on DTC Website - sharewise.com
Transcript : Eli Lilly and Company Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 10 - MarketScreener
Polar Capital Healthcare Trust reveals top holdings, led by Eli Lilly - Investing.com Australia
BMO Capital reiterates Outperform rating on Eli Lilly stock amid price cuts - Investing.com
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):